Calpis' AmealPeptide cuts BP in hypertensives

Data from two clinical trials presented by USA-based Calpis at the American Society of Hypertension annual meeting, in New Orleans, show that the milk-derived dietary supplement AmealPeptide reduces blood pressure in hypertensive patients.

According to the firm, the AHEAD II and PROBE studies confirmed the safety and efficacy of the ingredient for patients suffering from Stage I and Stage II hypertension. The AHEAD II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6 mmHg for the active group after six weeks of treatment. The change was both statistically and clinically significant. According to experts, just a 2 mmHg reduction in systolic blood pressure results in a 6% cut in mortality due to stroke and a 4% drop in mortality due to coronary heart disease.

Results of the PROBE trial showed AmealPeptide to have a dose-dependent blood pressure lowering trend and a reduction of daytime ambulatory blood pressure of 7.6 mmHg (